Muse Cells vs Mesenchymal Stem Cells: What the Research Actually Compares

Understanding Two Types of Regenerative Cells

The field of regenerative medicine has evolved to include multiple cell types, each with distinct characteristics and evidence bases. Among these, mesenchymal stem cells (MSCs) and multilineage-differentiating stress-enduring (Muse) cells represent two approaches that are often discussed but rarely compared directly. Both can be delivered intravenously, both originate from adult tissues, and both have been investigated in published clinical trials. Yet their biology, homing mechanisms, and the quality of evidence supporting each differ in meaningful ways.

Understanding these differences matters for patients considering regenerative options and for physicians evaluating candidacy. The comparison is not about which cell type is superior in all contexts, but rather what the published science actually demonstrates, where the evidence remains early-stage, and what remains unknown. This article examines the peer-reviewed literature comparing muse stem cells and conventional MSCs, focusing on their origins, markers, pluripotency-like behavior, survival after intravenous delivery, and the clinical trials that have tested each approach.

Origins and Identification: How Muse Stem Cells Differ from Conventional MSCs

Muse cells, by contrast, represent a rare subset of cells found within bone marrow, adipose tissue, and other connective tissues. Kuroda, Dezawa, and colleagues first characterized this population in 2010, identifying them by their expression of the pluripotency marker stage-specific embryonic antigen-3 (SSEA-3). Unlike conventional MSCs, which lack SSEA-3, Muse cells exhibit a stress-tolerance profile and a capacity to differentiate into cells from all three germ layers—endoderm, mesoderm, and ectoderm—under appropriate conditions. This pluripotency-like behavior distinguishes Muse cells from the more restricted differentiation potential of standard MSCs.

Wakao, Dezawa, and colleagues further demonstrated in 2011 that Muse cells could be expanded in culture without losing their SSEA-3 expression or their trilineage differentiation capacity. This finding suggested that Muse cells might retain a degree of developmental plasticity not typically seen in conventional MSCs. However, the clinical relevance of this laboratory observation remains investigational, and the extent to which pluripotency-like behavior translates to functional outcomes in living tissue is still being studied.

The isolation process also differs. Conventional MSCs are enriched by plastic adherence and passaged multiple times to generate large cell numbers. Muse cells, because they represent only a small fraction of the starting tissue (roughly one to three percent of marrow stromal cells), require additional sorting steps—often using SSEA-3 antibodies—to achieve a purified population. This technical difference influences manufacturing complexity, cost, and the consistency of the final product.

Homing, Survival, and Engraftment: Evidence from Preclinical and Early Clinical Studies

One of the most debated questions in intravenous cell therapy is whether delivered cells can home to damaged tissue, survive in that environment, and contribute to repair. For conventional MSCs, the evidence suggests that most intravenously delivered cells are trapped in the lungs shortly after infusion, with only a small percentage reaching other organs. The therapeutic effects observed in some MSC trials are thought to arise primarily from signaling molecules secreted by the cells rather than from long-term engraftment and differentiation.

Muse cells, in contrast, have been shown in preclinical models to exhibit a distinct homing mechanism. Yamada and colleagues demonstrated in 2018 that the sphingosine-1-phosphate (S1P) and S1P receptor 2 (S1PR2) signaling axis guides intravenously delivered Muse cells to sites of tissue injury. In laboratory models, damaged tissue releases S1P, which acts as a chemoattractant for Muse cells expressing S1PR2. This targeted migration appeared to improve the cells' accumulation in injured areas compared to conventional MSCs, which lack robust S1PR2 expression.

The Yamada study also reported that Muse cells could survive for extended periods in damaged tissue and differentiate into tissue-specific cell types in response to local cues. These observations were made in controlled laboratory models, however, and the degree to which this homing and engraftment occurs in human patients remains an area of active investigation. Small animal models do not always predict human physiology, and the microenvironment of human tissue injury is far more complex than laboratory conditions can replicate.

For MSCs, survival signals are less well characterized. Some studies suggest that MSCs undergo apoptosis within days of intravenous delivery, raising questions about whether transient signaling is sufficient to produce lasting benefit. Other research indicates that even short-lived MSC presence may be enough to modulate immune responses and initiate repair cascades. The picture is incomplete, and individual variation in recipient biology—immune status, inflammation levels, and tissue perfusion—likely influences outcomes in ways that are not yet fully understood.

Published Clinical Evidence: What the Trials Show and What They Do Not

The clinical evidence for MSCs spans decades and includes trials in a variety of conditions. Hare and colleagues published a randomized trial in 2009 examining the safety of intravenous allogeneic MSCs in a specific population. The study reported no serious adverse events attributable to the cells and provided early safety data for this delivery route. Importantly, the trial was designed primarily to assess safety rather than efficacy, and the authors noted that larger studies would be needed to draw conclusions about functional outcomes.

Bartolucci and colleagues reported in 2017 on a trial using umbilical-cord-derived MSCs, noting improvements in functional capacity and quality-of-life measures in the supported group. The study enrolled a relatively small number of participants and was not blinded, which limits the strength of the conclusions. The authors acknowledged that placebo effects, patient selection, and other confounding factors could have influenced the results. While encouraging, the findings remain early-stage and require replication in larger, well-controlled trials.

For Muse cells, the published clinical evidence is more recent and more limited in scope. Noda and colleagues reported in 2020 on a first-in-human Japanese safety study using a Muse cell product designated CL2020. The trial enrolled a small cohort and focused on establishing that intravenous Muse cell delivery could be performed without triggering immune reactions or other serious adverse events. No major safety signals were identified, and the product was well tolerated. Functional outcomes were exploratory endpoints, and the study was not powered to draw definitive conclusions about efficacy.

Niizuma and colleagues published a randomized, double-blind trial in 2023 that tested CL2020 in a larger population using a placebo-controlled design. The primary endpoint, a functional outcome measure, showed modest improvement in the Muse cell group compared to placebo, but the difference did not reach statistical significance in the full analysis. Secondary endpoints suggested some benefit in specific subgroups, but the authors emphasized that these findings were exploratory and that the overall results were not uniformly positive. The trial underscores an important reality: not every study in regenerative medicine yields dramatic results, and individual responses vary widely.

These trials represent the current state of published evidence for Muse cells. The research is early-stage, the patient populations are small, and the follow-up periods are relatively short. The same can be said for many MSC trials, despite the larger number of studies. Both cell types remain investigational in most clinical contexts, and neither has received approval from the U.S. Food and Drug Administration for widespread therapeutic use.

A Comparison Table: Proven, Early, and Unknown

This table summarizes what is known, what is emerging, and what remains uncertain. The literature does not support claims that either cell type is definitively superior across all applications. Rather, the evidence suggests that each has distinct biological properties that may be relevant in different contexts, and that both require further study to clarify their roles in regenerative medicine.

Physician-Led Screening and Evidence-Based Candidacy Evaluation

Given the early-stage nature of the evidence for both MSCs and Muse cells, physician-led evaluation becomes essential. Not every patient is a candidate for regenerative cell therapy, and not every clinical scenario has supporting data. A thorough candidacy assessment involves reviewing the patient's medical history, understanding the specific condition being addressed, and discussing the published evidence openly—including the studies that showed modest or null results.

Dr. Charles Pereyra, MD, emphasizes that regenerative cell therapy should never be positioned as having certain outcomes. The peer-reviewed literature reveals significant individual variation in responses, and factors such as age, inflammatory status, tissue vascularity, and concurrent medications all influence outcomes in ways that are not yet predictable. A responsible evaluation involves setting realistic expectations, explaining the limitations of the current evidence, and ensuring that patients understand they are participating in an investigational process.

For patients who have been told they need to travel overseas to access Muse cell therapy, physician-supervised options are available in the United States. These options operate under appropriate regulatory frameworks and involve transparent discussions of the evidence base. Choosing a provider who presents the science honestly—including the null and mixed-result trials—is as important as the cell type being used.

Dr. Charles Pereyra also points out that some patients may be better candidates for conventional MSCs, while others may benefit from exploring Muse cells based on their individual profile. The decision should be guided by the published literature relevant to the patient's condition, the quality of that evidence, and the patient's own values and risk tolerance. There is no one-size-fits-all answer, and the field is evolving as new trials are completed and published.

The Role of Transparent Communication and Ongoing Research

The comparison between Muse cells and MSCs highlights a broader challenge in regenerative medicine: balancing optimism about new technologies with intellectual honesty about the limitations of the data. Both cell types have shown promise in preclinical models and early human trials, but neither has yet produced the level of evidence required for regulatory approval in most contexts. The Niizuma trial's modest and mixed results serve as a reminder that even well-designed studies do not always yield clear-cut answers.

Patients considering regenerative cell therapy should ask specific questions: What published studies support this approach for my condition? Were those studies randomized and blinded? What were the outcome measures, and how large were the effect sizes? Were there negative or null findings in other trials? What percentage of patients in the published studies experienced meaningful benefit? These questions help distinguish evidence-based practice from marketing.

Ongoing research will continue to refine our understanding of both Muse cells and MSCs. New trials are underway, and some may provide clearer answers about which patients benefit most from which cell types. Until that data is available, the responsible approach is to proceed with cautious optimism, rigorous screening, and transparent communication about what is known and what is not.

Frequently Asked Questions

Are Muse cells more effective than conventional MSCs?

The published evidence does not support a blanket statement that one cell type is universally more effective than the other. Muse cells have shown distinct homing properties in preclinical models, and early human trials have established safety, but the clinical trials to date are small and exploratory. MSCs have a much larger body of evidence, though results vary widely across studies and conditions. Effectiveness depends on the specific application, patient characteristics, and the quality of the product being used.

Can Muse stem cells be used for joint or musculoskeletal concerns?

Investigational use of Muse cells for musculoskeletal applications is an area of emerging interest, but published clinical trial data in this specific context is limited. The pluripotency-like behavior and trilineage differentiation capacity observed in laboratory studies suggest potential, but translating those observations into functional outcomes in human joints requires rigorous clinical testing. MSCs, by contrast, have been studied more extensively in musculoskeletal contexts, though the evidence remains mixed and investigational.

What does the homing mechanism mean for patients receiving intravenous cell therapy?

The S1P-S1PR2 homing mechanism described in preclinical studies suggests that Muse cells may accumulate more efficiently at sites of tissue injury compared to conventional MSCs. However, this finding comes primarily from laboratory models, and the extent to which it translates to human physiology is still being investigated. Homing efficiency likely varies based on individual factors such as inflammation levels, tissue perfusion, and the specific injury being addressed. It is one of several variables that may influence outcomes, though individual responses vary.

Are these therapies approved by the FDA?

No. Neither Muse cells nor conventional MSCs are approved by the U.S. Food and Drug Administration for most regenerative applications. Both remain investigational, and patients considering these options should understand that they are participating in an evolving area of medicine where the evidence base is still being built. Physician-supervised use under appropriate frameworks allows access while maintaining safety and transparency, but approval for widespread therapeutic use has not been granted for either cell type in most clinical contexts.

At Springs Rejuvenation, stem cell and exosome therapies are used together as part of a personalized regenerative protocol.